# EDGAR Filing Document

**Accession Number:** 0001173281
**File Stem:** 0000000000-23-002765
**Filing Date:** 2023-3
**Character Count:** 3021
**Document Hash:** 6d573efb365e2947b81ca08f8ab7333b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002765.hdr.sgml**: 20230418

**ACCESSION NUMBER**: 0000000000-23-002765

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230320

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuBase Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001173281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 465622433
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 350 TECHNOLOGY DRIVE
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15219
- **BUSINESS PHONE:** 412-763-3350

**MAIL ADDRESS:**
- **STREET 1:** 350 TECHNOLOGY DRIVE
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15219

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ohr Pharmaceutical Inc
- **DATE OF NAME CHANGE:** 20090819

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BBM HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20070402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRIME RESOURCE INC
- **DATE OF NAME CHANGE:** 20020513
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001410578-22-003576

## Text-Extract

```

United States securities and exchange commission logo

                     March 20, 2023

       Todd Branning
       Chief Financial Officer
       NeuBase Therapeutics, Inc.
       350 Technology Drive
       Pittsburgh, PA 15219

                                                        Re: NeuBase
Therapeutics, Inc.
                                                            Form 10-K for the
Year Ended September 30, 2022
                                                            Filed December 21,
2022
                                                            File No. 1-35963

       Dear Todd Branning:

              We have completed our review of your filing. We remind you that
the company and its
       management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
       any review, comments, action or absence of action by the staff.

                     Sincerely,

                     Division of Corporation Finance

                     Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 20, 2023

Todd Branning
Chief Financial Officer
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219

Re: NeuBase Therapeutics, Inc.

Form 10-K for the Year Ended September 30, 2022

Filed December 21, 2022

File No. 1-35963

Dear Todd Branning:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences